Pandemic response efforts require nimble, dynamic thinking and a willingness to innovate. By embracing this mindset and championing a dynamic, collaborative response, SalivaDirect helped communities overcome challenges of the COVID-19 pandemic. What began with the development of an open-source, low-cost COVID-19 diagnostic assay at Yale School of Public Health has grown into a Global Diagnostic Network and a spinout into a new, independent nonprofit: SalivaDirect, Inc.
SalivaDirect Inc, the nonprofit, is continuing to propel the use of saliva as a superior sample type for accessible, equitable surveillance of respiratory pathogens. To date, more than 200 CLIA laboratories have provided over 7M SalivaDirect tests nationwide. SalivaDirect also has been independently validated internationally in 15+ countries.
Company Details
- Employees
- 8
- Founded
- -
- Address
- New Haven, Ct, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.salivadirect.org
- HQ
- New Haven, CT
Salivadirect, Inc. Questions
Salivadirect, Inc.'s website is http://www.salivadirect.org
Salivadirect, Inc.'s LinkedIn profile is https://www.linkedin.com/company/salivadirect
Salivadirect, Inc. has
8 employees.
View email and phone details for 8
employees at Salivadirect, Inc..
Salivadirect, Inc.'s industry is
Biotechnology Research
Salivadirect, Inc.'s top competitors are
Neelyx Labs,
Micoy Therapeutics,
Tezcat Biosciences,
Lung Cancer Research Foundation,
Georgia Life Sciences,
National Mental Health Corps,
Mirimus,
Academic Public Health Corps,
Biotia,
Yale New Haven Hospital.
Salivadirect, Inc.'s categories are Biotechnology Research
Salivadirect, Inc.'s founding year is 2020
